Such data led to the endorsement for the use of Oncotype DX RS by ASCO and NCCN as both a prediction and prognostic tool among women with estrogen receptor-positive node negative breast cancer. The two prototypes that have the most clinical data reported and are being evaluated in prospective ...
A molecular taxonomy for urothelial carcinoma. PURPOSE: Even though urothelial cancer is the fourth most common tumor type among males, progress in treatment has been scarce. A problem in day-to-day clinical practice is that precise assessment of individual tumors is still fairly unc... G Sjoda...
A better understanding of tumor host biology has led to improvements in the multidisciplinary management of breast cancer, and traditional pathological evaluation is being complemented by more sophisticated genomic approaches. A number of genomic biomarkers have been developed for clinical use, and ...
Targeting HER2/neu-positive breast cancer Positive results from five recent large randomized trials of adjuvant trastuzumab have shown how molecularly targeted therapy can dramatically improve clinical outcome. HER2/neu is an oncogene in the EGFR family that is over-...
Comments & Opinion27 Jan 2025Nature Reviews Clinical Oncology P: 1-2 Refining biomarker design in light of cancer evolution Insights from the TRACERx cohort suggest that the ORACLE biomarker might help to improve molecular prognostication in patients with lung tumors by accounting for spatiogenomic int...
In the observational ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial, children with high-risk cancer were treated with molecular tumor board-recommended therapies, resulting in overall clinical response rates that translated into survival benefit aft...
genomicstrial designClinical trials in breast cancer (BC) have seldom taken into consideration molecular heterogeneity, because most have been performed in ... S Loi,M Buyse,C Sotiriou,... - 《Current Opinion in Oncology》 被引量: 84发表: 2004年 Towards discovery-driven translational research ...
Vitamin C has been used in complementary and alternative medicine for cancers regardless of its ineffectiveness in clinical trials and the paradoxical effects antioxidants have on cancer. Vitamin C was found to induce cytotoxicity against cancers. However, the mechanisms of action have not been fully ...
Furthermore, we describe the presence of certain groups of antigens as putative targets for treatment, evaluate the outcomes of current clinical immunotherapy trials, and finally, we propose a strategy to better implement immuno-oncological markers to guide future immune therapies in BC....
For this class of tumors, screening could never be effective as the time span of tumor development is too short. The genomic structure of interval breast cancers should be pursued aggressively as these tumors carry a high mortality burden. As more patients are included in clinical trials that ...